Rankings
▼
Calendar
KROS
Keros Therapeutics, Inc.
$424M
Q1 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
Gross Profit
$0
0.0% margin
Operating Income
-$3M
-114.3% margin
Net Income
-$3M
-127.3% margin
EPS (Diluted)
$-0.41
Cash Flow
Operating Cash Flow
-$3M
Free Cash Flow
-$3M
Stock-Based Comp.
$11,000
Balance Sheet
Total Assets
$0
Total Liabilities
$0
Stockholders' Equity
$13M
Cash & Equivalents
-$23M
← FY 2019
All Quarters
Q2 2019 →
KROS Q1 2019 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena